Dr Patrick O’Neill of Pfizer, Ireland, and Professor Jie Wu of the National University of Singapore, and their team, have made groundbreaking advancements in the synthesis of 1,2,3-triazole – a key building block in the manufacture of a life-saving antibiotic. Replacing traditional batch processes, they developed a safer, more efficient method using continuous flow chemistry, which addresses potential global supply chain vulnerabilities. This innovative approach eliminates hazardous intermediates, improves reaction safety, and ensures a stable supply of 1,2,3-triazole for global pharmaceutical production.

A future where injured or diseased organs can be removed and replaced with new lab-printed tissues that are customized specifically for each patient is not as far away as you might think. These functional and living tissues could grow naturally within the body, and repair and sustain themselves over time. While these concepts were once in the realm of science fiction, advances in bioprinting, which is a form of 3D printing using biological “inks” (known as bioinks) loaded with living cells, are bringing them closer to reality. Among the researchers advancing this field is Dr. Mingjun Xie of Zhejiang University, China, and colleagues, who are performing work that addresses a significant challenge in bioprinting. This involves creating large portions of tissues that have a functional vasculature, thereby mimicking the complexity of native tissues and organs.